Together with a few prior case reports of POLE mutant and mismatch repair deficient IDH-wildtype glioblastomas with favorable clinical course and response to immune checkpoint blockade [7, 20, 24], our patient cohort further suggests that de novo RRD glioblastomas may have better clinical outcomes than conventional glioblastoma overall and potentially benefit from immune checkpoint blockade. Here, POLE is linked to glioblastoma.